Diabetic Nephropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Diabetic Nephropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major diabetic nephropathy markets reached a value of US$ 9,717.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14,572.9 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

The diabetic nephropathy market has been comprehensively analyzed in IMARC's new report titled "Diabetic Nephropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic nephropathy is a serious complication of diabetes that affects the kidneys. It occurs when high blood sugar levels over time damage the blood vessels and filtering units (glomeruli) in the kidneys, leading to a decrease in kidney function. Early symptoms of this ailment may not be noticeable, but as the disease progresses, patients may experience swelling in the legs, ankles, feet, or face, fatigue, worsening blood pressure control, nausea, vomiting, loss of appetite, difficulty sleeping, etc. Numerous other common indications associated with the illness include protein in the urine, confusion, shortness of breath, persistent itching, an increased need to urinate, etc. The diagnosis of diabetic nephropathy typically requires routine screening tests, such as albumin/creatinine ratio, glomerular filtration rate, urinary albumin test, etc. The healthcare provider may also perform various imaging studies, including X-rays and ultrasounds, to determine the structure and size of the kidney. In some cases, a biopsy is recommended, which involves the removal of small pieces of kidney tissue for medical examination.

The increasing prevalence of high blood pressure and diabetes, which directly damage blood vessels as well as other kidney cells, is primarily driving the diabetic nephropathy market. In addition to this, the rising incidences of numerous associated risk factors, such as obesity, high blood cholesterol, smoking, family history, etc., are also bolstering the market growth. Furthermore, the inflating utilization of effective medications, including angiotensin 2 receptor blockers and glucagon-like peptide-1 (GLP-1) receptor agonists, to help normalize high blood pressure and lower blood sugar levels is acting as another significant growth-inducing factor. Additionally, various government bodies and non-governmental organizations are taking initiatives to create awareness as well as improve access to educational programs, including behavioral counseling for individuals with diabetic nephropathy. This, in turn, is also propelling the market growth. Moreover, the emerging popularity of mesenchymal stem cell therapy for treating the condition since it prevents dialysis, eliminates the need for insulin injections, and lowers the risk of disease progression in patients is expected to drive the diabetic nephropathy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the diabetic nephropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic nephropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic nephropathy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diabetic nephropathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diabetic nephropathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diabetic nephropathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the diabetic nephropathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diabetic nephropathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diabetic nephropathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of diabetic nephropathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic nephropathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic nephropathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diabetic nephropathy across the seven major markets?
What is the size of the diabetic nephropathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diabetic nephropathy?
What will be the growth rate of patients across the seven major markets?

Diabetic Nephropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diabetic nephropathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic nephropathy market?
What are the key regulatory events related to the diabetic nephropathy market?
What is the structure of clinical trial landscape by status related to the diabetic nephropathy market?
What is the structure of clinical trial landscape by phase related to the diabetic nephropathy market?
What is the structure of clinical trial landscape by route of administration related to the diabetic nephropathy market?